Core Viewpoint - The company JinKai Life Science has shown significant growth in revenue and profit, driven by its CDMO services for pharmaceutical companies and benefiting from the depreciation of the RMB [4][8]. Group 1: Company Overview - JinKai Life Science Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009, with its IPO on August 3, 2023 [8]. - The company specializes in providing custom development and manufacturing services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [2][8]. - The main revenue sources include 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96% [8]. - The net profit attributable to the parent company was 103 million yuan, showing a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 61.18% of total revenue [4]. - The company is involved in various concepts including CRO, weight loss drugs, Alzheimer's-related services, and fluorochemical products [2][3]. - The stock has seen a recent increase in trading volume and interest, with a significant net inflow of 8.75 million yuan on the latest trading day [5][6].
金凯生科涨4.78%，成交额3.83亿元，近3日主力净流入247.73万